Plenary Presentation at EORTC-NCI-AACR 32 nd Symposium on Molecular Targets and Cancer Therapeutics Describes Encouraging Tolerability and Exposure Profiles for RMC-4630 Combined with Cobimetinib and ...

Investigator-initiated multicenter Phase I study in glioblastoma with CAXII-targeting, 177 Lu radiolabeled antibody Fab fragment (LuCaFab) in preparation, led by University of Münster as the sponsor ...

The ongoing, open-label, multicenter trial is a Phase 1/1b study evaluating the safety profile and clinical activity of AB680 in combination with nab-paclitaxel plus gemcitabine (NP/Gem) and ...

PALO ALTO, CA, USA I September 26, 2016 I Orbus Therapeutics Inc., a private, clinical-stage biopharmaceutical company focused on the development and commercialization of therapies that treat rare ...

REDWOOD CITY, CA, USA I April 08, 2018 I Menlo Therapeutics Inc. (NASDAQ:MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus ...

Princeton-based international specialty pharma company partners with Baylor College of Medicine Princeton-based BBI, an international specialty pharmaceutical company, also will participate in ...

– Combination Designed to Create Leading Specialty Healthcare Company with Expanded Platform for Future Growth – Addition of Auxilium’s Leading Men’s Health Products and Development Portfolio Expected ...

Boehringer Ingelheim and Lilly present full results from EASE Phase III program for empagliflozin as adjunct to insulin in type 1 diabetes ...

Two Preclinical Data Poster Presentations at the 2011 World Molecular Imaging Congress TUSTIN, CA, USA | September 12, 2011 | Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage ...

SAN FRANCISCO, CA, USA I January 27, 2016 I FibroGen, Inc. (FibroGen) today announced early results from a Phase 2, randomized, open-label study of FG-3019, an investigational anti-fibrotic antibody, ...

NEW YORK, NY, USA & SEOUL, South Korea I April 23, 2014 I Bristol-Myers Squibb Company (NYSE:BMY) and Samsung BioLogics today announced the companies will increase the scope of their existing ...

QUEBEC CITY, Canada I July 28, 2015 I Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the “Company”) today announced that it has granted to German life sciences entrepreneurs with a proven ...